These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anticancer drug development at the US National Cancer Institute. Takimoto CH. Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935 [Abstract] [Full Text] [Related]
3. History of the National Cancer Institute and the plant screening program. Schepartz SA. Cancer Treat Rep; 1976 Aug; 60(8):975-7. PubMed ID: 791487 [No Abstract] [Full Text] [Related]
4. Update on NCI in vitro drug screen utilities. Holbeck SL. Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034 [Abstract] [Full Text] [Related]
5. The preclinical new drug research program of the National Cancer Institute. Driscoll JS. Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438 [Abstract] [Full Text] [Related]
6. Cancer research program strategy and planning--the use of contracts for program implementation. Baker CG. J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):651-69. PubMed ID: 328910 [No Abstract] [Full Text] [Related]
7. Origins and development of chemotherapy research at the National Cancer Institute. Zubrod CG. Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871 [No Abstract] [Full Text] [Related]
8. As memory serves--an informal history of the National Cancer Institute, 1937-57. Shimkin MB. J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):559-600. PubMed ID: 328903 [No Abstract] [Full Text] [Related]
9. Historical background of the National Cancer Institute's drug development thrust. Zubrod CG, Schepartz SA, Carter SK. Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156 [No Abstract] [Full Text] [Related]
10. The role of the National Cancer Institute in drug development. Doroshow J. Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
11. In the middle: 1954---63--historical note. Shimkin MB. J Natl Cancer Inst; 1979 May; 62(5):1295-317. PubMed ID: 220451 [No Abstract] [Full Text] [Related]
12. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Wallqvist A, Monks A, Rabow AA, Thanki N, Shoemaker RH, Covell DG. Prog Cell Cycle Res; 2003 May; 5():173-9. PubMed ID: 14593711 [Abstract] [Full Text] [Related]
15. The history of complementary and alternative medicine in the US. Rosenbaum CC. Ann Pharmacother; 2007 Jul; 41(7):1256-60. PubMed ID: 17578880 [No Abstract] [Full Text] [Related]
16. Intramural research pioneers, personalities, and programs: the early years. Dunn TB. J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):605-16. PubMed ID: 328905 [No Abstract] [Full Text] [Related]
17. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Monga M, Sausville EA. Leukemia; 2002 Apr; 16(4):520-6. PubMed ID: 11960328 [Abstract] [Full Text] [Related]
19. Developing new agents for the treatment of childhood cancer. Kurmasheva R, Morton C, Houghton PJ. Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407 [Abstract] [Full Text] [Related]
20. History of the Journal of the National Cancer Institute. Weisburger EK. J Natl Cancer Inst; 1977 Aug; 59(2 Suppl):601-4. PubMed ID: 328904 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]